Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

Colorados First Licensed Cannabis Rd Firm To Study Marijuanas Effect On Alzheimers Disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Read the rest of this story on DenverPost.com.

Like This??? >>>PLEASE SHARE IT<<<

Author: admin

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.